These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 476014

  • 1. The treatment of advanced cystadenocarcinoma of the ovary with gestronol and continuous oral cyclophosphamide.
    Guthrie D.
    Br J Obstet Gynaecol; 1979 Jul; 86(7):497-500. PubMed ID: 476014
    [Abstract] [Full Text] [Related]

  • 2. Cyclic GMP in urine to monitor the response to ovarian cancer to therapy.
    Turner GA, Ellis RD, Guthrie D, Latner AL, Ross WM, Skillen AW.
    Br J Obstet Gynaecol; 1982 Sep; 89(9):760-4. PubMed ID: 6288064
    [Abstract] [Full Text] [Related]

  • 3. Factors influencing ovarian cancer survival after chemotherapy.
    Webb MJ, Malkasian GD, Jorgensen EO.
    Obstet Gynecol; 1974 Oct; 44(4):564-70. PubMed ID: 4413425
    [No Abstract] [Full Text] [Related]

  • 4. [The effect of various factors on the results of chemotherapy in patients with recurrent ovarian serous cystadenocarcinoma].
    Dzhilavian GA, Vinokurov VL.
    Vopr Onkol; 1984 Oct; 30(3):16-21. PubMed ID: 6424327
    [Abstract] [Full Text] [Related]

  • 5. Chemotherapy of advanced ovarian carcinoma: a prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide.
    Young RC, Canellos GP, Chabner BA, Schein PS, Hubbard SP, DeVita VT.
    Gynecol Oncol; 1974 Dec; 2(4):489-97. PubMed ID: 4376998
    [Abstract] [Full Text] [Related]

  • 6. [Clinical characteristics of clear cell carcinoma of the ovary].
    Shi M, Zhang Y, Shen K, Lang J, Huang H, Wu M.
    Zhonghua Fu Chan Ke Za Zhi; 2002 Mar; 37(3):161-3. PubMed ID: 11953086
    [Abstract] [Full Text] [Related]

  • 7. Cyclophosphamide and floxuridine adjuvant chemotherapy for stage III and IV carcinoma of the ovary.
    VillaSanta U.
    Gynecol Oncol; 1980 Aug; 10(1):44-50. PubMed ID: 6447099
    [No Abstract] [Full Text] [Related]

  • 8. High-dose, short-duration cisplatin/doxorubicin combination chemotherapy for advanced ovarian epithelial cancer.
    Hunter RE, Griffin TW, Stevens S, Roman LD, Bokhari F, Reale FR, Tak WK, Fitzgerald TJ, Dillon MB, Rose PG.
    Cancer; 1991 Nov 01; 68(9):1890-4. PubMed ID: 1655227
    [Abstract] [Full Text] [Related]

  • 9. Quadrichemotherapy for advanced ovarian carcinoma.
    Kessinger A, Foley JF, Lemon HM.
    Obstet Gynecol; 1976 Aug 01; 48(2):134-6. PubMed ID: 940644
    [Abstract] [Full Text] [Related]

  • 10. Progestogen therapy for ovarian carcinoma.
    Timothy I.
    Br J Obstet Gynaecol; 1982 Jul 01; 89(7):561-3. PubMed ID: 7093171
    [No Abstract] [Full Text] [Related]

  • 11. Chemotherapy of advanced ovarian carcinoma: initial experience using a platinum-based combination.
    Williams CJ, Mead B, Arnold A, Green J, Buchanan R, Whitehouse M.
    Cancer; 1982 May 01; 49(9):1778-83. PubMed ID: 6280845
    [Abstract] [Full Text] [Related]

  • 12. [The value of etoposide (VP-16) in the therapy of refractory ovarian cancer].
    Marth C, Pointner E, Zeimet AG, Abfalter E, Koza A, Windbichler G, Hetzel H, Dapunt O.
    Geburtshilfe Frauenheilkd; 1993 May 01; 53(5):303-7. PubMed ID: 8514100
    [Abstract] [Full Text] [Related]

  • 13. [Prognostic factors and better survival rate after the treatment of advanced ovarian cancer with neoadjuvant chemotherapy].
    Ivanov S, Ivanov S, Khadzhiolov N.
    Akush Ginekol (Sofiia); 2004 May 01; 43(6):17-9. PubMed ID: 15669647
    [Abstract] [Full Text] [Related]

  • 14. [Efficacy of mono- and polychemotherapy in patients with advanced ovarian cancer].
    Khasanova DT, Kotova DG.
    Vopr Onkol; 1984 May 01; 30(3):67-71. PubMed ID: 6369776
    [Abstract] [Full Text] [Related]

  • 15. A phase II study of mitozantrone in advanced carcinoma of the ovary.
    Coleman R, Clarke J, Gore M, Wiltshaw E, Slevin M, Harper P.
    Cancer Chemother Pharmacol; 1989 May 01; 24(3):200-2. PubMed ID: 2736711
    [Abstract] [Full Text] [Related]

  • 16. Carboplatin/cyclophosphamide combination chemotherapy for advanced ovarian cancer.
    Teeling M, Hayes Y, Fitzmaurice B, McGing P, Carney DN.
    Semin Oncol; 1992 Feb 01; 19(1 Suppl 2):102-6. PubMed ID: 1411620
    [Abstract] [Full Text] [Related]

  • 17. Treatment of 126 cases of advanced ovarian carcinoma with cyclophosphamide.
    Beck RE, Boyes DA.
    Can Med Assoc J; 1968 Mar 16; 98(11):539-41. PubMed ID: 5647240
    [No Abstract] [Full Text] [Related]

  • 18. [A randomized clinical trial of cyclophosphamide versus adriamycin, cyclophosphamide, 5-fluorouracil and methotrexate in advanced ovarian carcinoma--a preliminary report ].
    Chylak V, Ilijas M, Krusić J, Kolarić K.
    Lijec Vjesn; 1982 Mar 16; 104(3-4):120-2. PubMed ID: 6750298
    [No Abstract] [Full Text] [Related]

  • 19. [Tissue reaction in ovarian carcinoma after cyclophosphamide (Endoxan) therapy].
    Engeler V, Hanski W.
    Pathol Microbiol (Basel); 1969 Mar 16; 33(3):153-60. PubMed ID: 5350583
    [No Abstract] [Full Text] [Related]

  • 20. Response to second line chemotherapy in ovarian cancer of epithelial origin.
    Menczer J, Baitner S, Modan M, Chaitchik S, Brenner H.
    Eur J Cancer Clin Oncol; 1981 Dec 16; 17(12):1259-62. PubMed ID: 7200025
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.